The past couple of years have been eventful for Bluebird Bio (BLUE -6.80%). In 2022, the gene-editing specialist earned approval for two therapies in the U.S.: Zynteglo, which treats the beta thalassemia (TDT) genetic blood condition, and Skysona, a treatment for cerebral adrenoleukodystrophy (CALD), an inherited disorder that attacks nerve sheaths in the brain. And last year, Bluebird Bio got the green light for yet another gene-editing treatment, Lyfgenia, which targets sickle cell disease (SCD). The appr ...

Investing in biotech stocks is a tricky and risky endeavor, but there's a lot investors can do to increase their chances of success -- or at least avoid total failure and the loss of their funds.Here are three quick tricks that'll help to guide your biotech investments. You'll find them to be the most useful when you're evaluating whether to buy shares of a given company, but they'll also help you to understand when one of your holdings is entering a risky period.1. Cash comes firstMany of the biggest oppor ...

Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (CRSP -0.34%) this year. The stock is up more than 60% in 2023 after the company earned Food and Drug Administration (FDA) approval for its first treatment, Casgevy.CRISPR Therapeutics is transitioning into a commercial-stage company. But new drug launches can be unpredictable, and Casgevy, which it developed with partner Vertex Pharmaceuticals (VRTX 0.10%), will be breaking a lot of new gr ...

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - Chief Executive Officer Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - Chief Financial Officer Conference Call Participants Dane Leone - RJF Jason Gerberry - Bank of America Securities Eric Joseph - JPMorgan Jack Allen - Baird Gena Wang - Barclays Mani Foroohar - Leerink Eric Schmidt - Cantor Fitzgerald ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num ...

bluebird bio, Inc. (NASDAQ:BLUE) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Courtney O'Leary - IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Rich Colvin - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Jason Gerberry - Bank of America Eric Joseph - JPMorgan Gena Wang - Barclays Jack Allen - Baird Luca Issi - RBC Capital Yanan Zhu - Wells Fargo Brooke Schuster - William Blair Operator Goo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ FORM 10-K ___________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...